Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials

The economic impact of diabetes through lost labour force participation on individuals and government: evidence from a microsimulation model

(2014) Deborah Schofield et al.   BMC PUBLIC HEALTH

Liraglutide therapy in obese people with type 2 diabetes — Experience of a weight management centre

(2014) Hanaa Elkhenini et al.   European Journal of Internal Medicine

Identification of Direct and Indirect Social Network Effects in the Pathophysiology of Insulin Resistance in Obese Human Subjects

(2014) Christian H. C. A. Henning et al.   PLoS One

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Summary and Future Directions: Figure 1

(2013) Rose A. Gubitosi-Klug et al.   DIABETES CARE

Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

(2013) John M. Lachin et al.   DIABETES CARE

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials

(2013) B. Wang et al.   DIABETES OBESITY & METABOLISM

Vildagliptin more effectively achieves a composite endpoint of HbA1c

(2013) Giovanni Bader et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy

(2013) Qian Xu et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Global estimates of diabetes prevalence for 2013 and projections for 2035

(2013) L. Guariguata et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study

(2013) Sun H. Kim et al.   DIABETOLOGIA

Diabetic Retinopathy

(2013) Daniel F. Rosberger   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Blood pressure and diabetes: a fatal attraction

(2013) B. Williams   EUROPEAN HEART JOURNAL

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model

(2013) Vadivel Parthsarathy et al.   PLoS One

Evaluation of the Endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses

(2013) Nikola Panic et al.   PLoS One

Role of insulin resistance in endothelial dysfunction

(2013) Ranganath Muniyappa et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

(2013) Louise E Robinson et al.   BMJ Open

Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats (Gato-Kakizaki大鼠使用利拉鲁肽进行早期干预可以保护胰腺β细胞)

(2013) Xiu Luo et al.   Journal of Diabetes

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

(2012) Chun-jun Li et al.   Cardiovascular Diabetology

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

(2012) T. Forst et al.   DIABETIC MEDICINE

Complementary approaches to estimation of the global burden of diabetes

(2012) Nigel Unwin et al.   LANCET

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

(2009) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

(2008) Y. Seino et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

(2008) T. Vilsbøll et al.   DIABETIC MEDICINE